Pluriomics has signed an agreement to license iPS Academia Japan’s patents related to induced pluripotent stem cell (iPS cell) technologies. This agreement will enable Pluriomics to develop and commercialize iPS cell derived cells and culture media for use in basic research, drug discovery & development.
The patents related to iPS cell technologies licensed by iPS Academia Japan are the result of the groundbreaking research of Professor Shinya Yamanaka of the Center for iPS Cell Research and Application (CiRA) at Kyoto University, Japan. iPS cells hold immense potential for drug development and disease modeling. Patient-derived cells can be reprogrammed using iPS cell technology and subsequently differentiated into specific cell types of diverse lineages. This enables researchers to develop patient-specific cell lines for, among other applications, screening potential treatments. The personalized nature of this approach ensures greater predictive accuracy in terms of disease modeling and treatment outcome.
Stefan Braam, CSO of Pluriomics, commented: “Pluriomics’ goal is to support researchers to make better medicines faster. Pluriomics provides the most predictive human cellular models to improve and accelerate drug discovery & development. This contributes to reduction of animal toxicity testing.”
This agreement will ensure that Pluriomics continues to grow its range of Pluricyte cells and media. Its first product, Pluricyte Cardiomyocytes, are cardiomyocytes of predominantly the ventricular subtype and the most mature in the industry. Pluriomics’ serum-free chemically defined culture media allow highly reproducible cell cultures from batch-to-batch and vial-to-vial, which is critical in the complex and time and cost-intensive process of pharmaceutical drug development. Pluricyte Cardiomyocytes answer to the regulatory and societal push to find in-vitro alternatives to replace animal toxicity testing.
Pluriomics is an emerging biotechnology company, whose mission is to deliver innovative human cardiomyocyte models for use in drug discovery and development. Pluriomics’ ambition is to implement its Pluricyte cell based models at various stages of drugs discovery to improve decision-making, reduce attrition rates and provide an alternative to animal testing. Pluriomics, with R&D based in Leiden, The Netherlands and manufacturing facilities in Gosselies, Belgium was founded in 2010. Its Pluricyte cardiomyocyte models are derived from iPS cell technology and based upon patented technologies. To learn more about how Pluriomics facilitates life science research, please visit www.pluriomics.com.
About iPS Academia Japan, Inc.
iPS Academia Japan, Inc. (AJ) is an affiliate of Kyoto University, and its main role is to manage and utilize the patents and other intellectual properties held/controlled by Kyoto University and other universities in the field of iPS cell technologies so that the research results contribute to health and welfare worldwide. AJ was established in Kyoto in June 2008. AJ’s patent portfolio consists of more than 70 patent families (the total number of patent applications is about 320 cases) in the iPS cell technology as of April 2015, and about 120 license arrangements have been executed with domestic or international entities. For more information, visit www.ips-cell.net.
Stefan Braam – stefan.braam(at)pluriomics.com